Table of Contents
Introduction
Diagnosis
DDx
Rx
phaeochromocytoma
see also:
catecholamines and sympathomimetics
adrenal tumours
carcinoid tumour
Introduction
pheochromocytomas arise from chromaffin cells and which secrete catecholamines
they are rare tumours, arising in only 2-8 people per million population
85% arise from the adrenal (11% are malignant), 15% arise from extra-adrenal sources such as sympathetic ganglia (30% are malignant)
accounts for ~10% of adrenal masses and 10% of cases are bilateral - see
adrenal tumours
15–20% are hereditary
mostly occurs in young or middle age adults
they were 1st described in 1886 by Felix Fränkel, and the name was coined by Ludwig Pick in 1912
Diagnosis
often evident from clinical picture:
episodic hypertension, headache, sweating, palpitations, anxiety, pallor and tremors
may cause
adrenergic storm
may be associated with endocrine syndromes such as:
neurofibromatosis
von Hippel-Lindau disease (retinal angiomas) - this accounts for 5% of cases
multiple endocrine neoplasm II (medullary thyroid carcinoma)
easy to detect on MRI
diagnostic tests include:
plasma catecholamines (>2000 pg/mL) - lower levels may require further Ix such as a clonidine suppression test
24hr urinary metanephrines >1.6 mg/24 hr
NB.
metamphetamine (ice) users
may also have high urinary metanephrine levels and thus should have a week of abstinence before re-testing
DDx
withdrawal syndromes eg.
opiate withdrawal
paragangliomas
other causes of hypertension
hyperthyroidism
carcinoid tumour
insulinoma
mercury poisoning
alpha adrenergic agonists
toxicity / overdose
other causes of excess catecholamine / sympathomimetic activity may cause a false positive urine catecholamine or metanephrine test:
stress / exertion
hypoglycaemia
methyldopa, ganglion blockers
stimulants including caffeine
dopamine agonists
metamphetamine (ice) use
Rx
Rx is usually surgical resection but there is a considerable risk of profound hypotension post-op which is usually prevented by measures such as pre-op salt loading
3% recur
patients have a relative risk of 3-4x of secondary cancers